Bristol-Myers Squibb (NYSE:BMY) shares bought by V Square Quantitative Management LLC

V Square Quantitative Management LLC raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 100.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,034 shares of the biopharmaceutical company’s stock after acquiring an additional 17,016 shares during the period. V Square Quantitative Management LLC’s holdings in Bristol-Myers Squibb were worth $1,746,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. lifted its position in Bristol-Myers Squibb by 532.7% in the fourth quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $96,000 after buying an additional 1,582 shares during the last quarter. Institute for Wealth Management LLC. raised its stake in Bristol-Myers Squibb by 1.0% in the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 296 shares during the period. Great Diamond Partners LLC raised its stake in Bristol-Myers Squibb by 9.2% in the 4th quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 367 shares. actions during that period. Principal Securities Inc. acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $1,139,000. Finally, Scotia Capital Inc. boosted its stake in Bristol-Myers Squibb by 48.6% during the 4th quarter. Scotia Capital Inc. now owns 236,724 shares of the biopharmaceutical company’s stock valued at $12,146,000 after buying an additional 77,471 shares during the period. 76.41% of the shares are owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb stock opened at $41.20 on Friday. The company’s 50-day simple moving average is $44.50, and its 200-day simple moving average is $48.73. The company has a market cap of $83.52 billion, a P/E ratio of -13.29, a price-to-earnings-growth ratio of 14.04 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11, and a quick ratio of 0.99. Bristol-Myers Squibb has a fifty-two week low of $39.91 and a fifty-two week high of $66.38.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period last year, the firm posted earnings of $2.05 per share. As a group, equities research analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Wall Street analysts are predicting an increase

Several equities analysts have commented on the stock. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 23rd. Barclays lowered their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. BMO Capital Markets cut their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th . Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $60.00, according to MarketBeat.com.

Get the latest stock report on BMY

About Bristol-Myers Squibb

(Free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.